3 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 19 points (-0.1%) at 13,006 as of Monday, Dec. 3, 2012, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,239 issues advancing vs. 1,655 declining with 129 unchanged.

The Health Care sector currently sits down 0.4% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Regeneron Pharmaceuticals ( REGN), up 2.3%, Fresenius Medical Care Corporation ( FMS), up 1.2%, Valeant Pharmaceuticals International ( VRX), up 1.2%, Sanofi ( SNY), up 1.1% and Biogen Idec ( BIIB), up 1.1%. On the negative front, top decliners within the sector include DaVita HealthCare Partners ( DVA), down 1.0%, St Jude Medical ( STJ), down 1.2%, Express Scripts ( ESRX), down 0.9%, UnitedHealth Group ( UNH), down 0.7% and Intuitive Surgical ( ISRG), down 0.6%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector higher today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $2.43 (1.5%) to $161.10 on light volume Thus far, 115,223 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 441,800 shares. The stock has ranged in price between $160.23-$161.36 after having opened the day at $160.45 as compared to the previous trading day's close of $158.67.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $92.9 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 39.0% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Novo Nordisk A/S Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday